262 related articles for article (PubMed ID: 26095883)
1. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions.
Highley JR; Lorente Pons A; Cooper-Knock J; Wharton SB; Ince PG; Shaw PJ; Wood J; Kirby J
Neuropathol Appl Neurobiol; 2016 Jun; 42(4):377-89. PubMed ID: 26095883
[TBL] [Abstract][Full Text] [Related]
2. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.
Hart MP; Brettschneider J; Lee VM; Trojanowski JQ; Gitler AD
Acta Neuropathol; 2012 Aug; 124(2):221-30. PubMed ID: 22526021
[TBL] [Abstract][Full Text] [Related]
3. Intermediate-length CAG repeat in ATXN2 is associated with increased risk for amyotrophic lateral sclerosis in Brazilian patients.
Tavares de Andrade HM; Cintra VP; de Albuquerque M; Piccinin CC; Bonadia LC; Duarte Couteiro RE; Sabino de Oliveira D; Claudino R; Magno Gonçalves MV; Dourado MET; de Souza LC; Teixeira AL; de Godoy Rousseff Prado L; Tumas V; Bulle Oliveira AS; Nucci A; Lopes-Cendes I; Marques W; França MC
Neurobiol Aging; 2018 Sep; 69():292.e15-292.e18. PubMed ID: 29934271
[TBL] [Abstract][Full Text] [Related]
4. Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with ATXN2 intermediate repeat expansions.
Tan RH; Kril JJ; McGinley C; Hassani M; Masuda-Suzukake M; Hasegawa M; Mito R; Kiernan MC; Halliday GM
Ann Neurol; 2016 Feb; 79(2):295-305. PubMed ID: 26599997
[TBL] [Abstract][Full Text] [Related]
5. C9orf72 hexanucleotide repeat expansions and Ataxin 2 intermediate length repeat expansions in Indian patients with amyotrophic lateral sclerosis.
Narain P; Gomes J; Bhatia R; Singh I; Vivekanandan P
Neurobiol Aging; 2017 Aug; 56():211.e9-211.e14. PubMed ID: 28527524
[TBL] [Abstract][Full Text] [Related]
6. Intermediate-length polyglutamine in ATXN2 is a possible risk factor among Eastern Chinese patients with amyotrophic lateral sclerosis.
Lu HP; Gan SR; Chen S; Li HF; Liu ZJ; Ni W; Wang N; Wu ZY
Neurobiol Aging; 2015 Mar; 36(3):1603.e11-4. PubMed ID: 25457026
[TBL] [Abstract][Full Text] [Related]
7. TDP-43 levels in the brain tissue of ALS cases with and without
Yang Y; Halliday GM; Kiernan MC; Tan RH
Neurology; 2019 Nov; 93(19):e1748-e1755. PubMed ID: 31619481
[TBL] [Abstract][Full Text] [Related]
8. Analysis of ATXN2 trinucleotide repeats in Korean patients with amyotrophic lateral sclerosis.
Kim YE; Oh KW; Noh MY; Park J; Kim HJ; Park JE; Ki CS; Kim SH
Neurobiol Aging; 2018 Jul; 67():201.e5-201.e8. PubMed ID: 29665996
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous ALS and SCA2 associated with an intermediate-length
Ghahremani Nezhad H; Franklin JP; Alix JJP; Moll T; Pattrick M; Cooper-Knock J; Shanmugarajah P; Beauchamp NJ; Hadjivissiliou M; Paling D; Mcdermott C; Shaw PJ; Jenkins TM
Amyotroph Lateral Scler Frontotemporal Degener; 2021 Nov; 22(7-8):579-582. PubMed ID: 33284045
[TBL] [Abstract][Full Text] [Related]
10. Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions.
Watanabe R; Higashi S; Nonaka T; Kawakami I; Oshima K; Niizato K; Akiyama H; Yoshida M; Hasegawa M; Arai T
Acta Neuropathol Commun; 2020 Oct; 8(1):176. PubMed ID: 33115537
[TBL] [Abstract][Full Text] [Related]
11. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.
Cooper-Knock J; Hewitt C; Highley JR; Brockington A; Milano A; Man S; Martindale J; Hartley J; Walsh T; Gelsthorpe C; Baxter L; Forster G; Fox M; Bury J; Mok K; McDermott CJ; Traynor BJ; Kirby J; Wharton SB; Ince PG; Hardy J; Shaw PJ
Brain; 2012 Mar; 135(Pt 3):751-64. PubMed ID: 22366792
[TBL] [Abstract][Full Text] [Related]
12. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
[TBL] [Abstract][Full Text] [Related]
13. ATXN2 trinucleotide repeat length correlates with risk of ALS.
Sproviero W; Shatunov A; Stahl D; Shoai M; van Rheenen W; Jones AR; Al-Sarraj S; Andersen PM; Bonini NM; Conforti FL; Van Damme P; Daoud H; Del Mar Amador M; Fogh I; Forzan M; Gaastra B; Gellera C; Gitler AD; Hardy J; Fratta P; La Bella V; Le Ber I; Van Langenhove T; Lattante S; Lee YC; Malaspina A; Meininger V; Millecamps S; Orrell R; Rademakers R; Robberecht W; Rouleau G; Ross OA; Salachas F; Sidle K; Smith BN; Soong BW; Sorarù G; Stevanin G; Kabashi E; Troakes C; van Broeckhoven C; Veldink JH; van den Berg LH; Shaw CE; Powell JF; Al-Chalabi A
Neurobiol Aging; 2017 Mar; 51():178.e1-178.e9. PubMed ID: 28017481
[TBL] [Abstract][Full Text] [Related]
14. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.
Yu Z; Zhu Y; Chen-Plotkin AS; Clay-Falcone D; McCluskey L; Elman L; Kalb RG; Trojanowski JQ; Lee VM; Van Deerlin VM; Gitler AD; Bonini NM
PLoS One; 2011 Mar; 6(3):e17951. PubMed ID: 21479228
[TBL] [Abstract][Full Text] [Related]
15. The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway.
Ciura S; Sellier C; Campanari ML; Charlet-Berguerand N; Kabashi E
Autophagy; 2016 Aug; 12(8):1406-8. PubMed ID: 27245636
[TBL] [Abstract][Full Text] [Related]
16. ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion.
Chiò A; Mora G; Sabatelli M; Caponnetto C; Lunetta C; Traynor BJ; Johnson JO; Nalls MA; Calvo A; Moglia C; Borghero G; Trojsi F; La Bella V; Volanti P; Simone I; Salvi F; Logullo FO; Riva N; Carrera P; Giannini F; Mandrioli J; Tanel R; Capasso M; Tremolizzo L; Battistini S; Murru MR; Origone P; Zollino M; Penco S; ; ; Mazzini L; D'Alfonso S; Restagno G; Brunetti M; Barberis M; Conforti FL
Neurobiol Aging; 2016 Mar; 39():218.e5-8. PubMed ID: 26733254
[TBL] [Abstract][Full Text] [Related]
17. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.
Lee T; Li YR; Ingre C; Weber M; Grehl T; Gredal O; de Carvalho M; Meyer T; Tysnes OB; Auburger G; Gispert S; Bonini NM; Andersen PM; Gitler AD
Hum Mol Genet; 2011 May; 20(9):1697-700. PubMed ID: 21292779
[TBL] [Abstract][Full Text] [Related]
18. ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis.
Li PP; Sun X; Xia G; Arbez N; Paul S; Zhu S; Peng HB; Ross CA; Koeppen AH; Margolis RL; Pulst SM; Ashizawa T; Rudnicki DD
Ann Neurol; 2016 Oct; 80(4):600-15. PubMed ID: 27531668
[TBL] [Abstract][Full Text] [Related]
19. ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry.
Borghero G; Pugliatti M; Marrosu F; Marrosu MG; Murru MR; Floris G; Cannas A; Parish LD; Cau TB; Loi D; Ticca A; Traccis S; Manera U; Canosa A; Moglia C; Calvo A; Barberis M; Brunetti M; Renton AE; Nalls MA; Traynor BJ; Restagno G; Chiò A;
Neurobiol Aging; 2015 Oct; 36(10):2906.e1-5. PubMed ID: 26208502
[TBL] [Abstract][Full Text] [Related]
20. The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.
Gispert S; Kurz A; Waibel S; Bauer P; Liepelt I; Geisen C; Gitler AD; Becker T; Weber M; Berg D; Andersen PM; Krüger R; Riess O; Ludolph AC; Auburger G
Neurobiol Dis; 2012 Jan; 45(1):356-61. PubMed ID: 21889984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
